Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 |
Tel: | N/A |
Website: | savarapharma.com |
IR: | See website |
Key People | ||
Matthew Pauls Chairman of the Board, Chief Executive Officer | David L. Lowrance Chief Financial & Administrative Officer, Secretary | Robert Matthew Lutz Chief Operating Officer | Raymond Dennis Pratt Chief Medical Officer |
Business Overview |
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations. |
Financial Overview |
For the fiscal year ended 31 December 2023, Savara Inc revenues was not reported. Net loss increased 43% to $54.7M. Higher net loss reflects pharmaceuticals segment loss increase of 55% to $60M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.25 to -$0.33. |
Employees: | 37 as of Mar 7, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $525.76M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$59.93M as of Dec 31, 2023 |
Net annual income (TTM): | -$54.70M as of Dec 31, 2023 |
Free cash flow (TTM): | -$51.36M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 138,148,141 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |